{"id":"https://openalex.org/W4387950206","doi":"https://doi.org/10.1007/s40262-023-01317-4","title":"A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects","display_name":"A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects","publication_year":2023,"publication_date":"2023-10-26","ids":{"openalex":"https://openalex.org/W4387950206","doi":"https://doi.org/10.1007/s40262-023-01317-4","pmid":"https://pubmed.ncbi.nlm.nih.gov/37882999","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10684410"},"language":"en","primary_location":{"id":"doi:10.1007/s40262-023-01317-4","doi":"https://doi.org/10.1007/s40262-023-01317-4","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-023-01317-4","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-023-01317-4.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s40262-023-01317-4.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076259754","display_name":"Hironobu Tsukada","orcid":"https://orcid.org/0009-0009-8039-7194","observed_orcids":["https://orcid.org/0009-0009-8039-7194"]},"institutions":[{"id":"https://openalex.org/I4210140088","display_name":"Sumitomo Dainippon Pharma (United States)","ror":"https://ror.org/04vwbmb32","country_code":"US","type":"company","lineage":["https://openalex.org/I31591830","https://openalex.org/I4210140088"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hironobu Tsukada","raw_affiliation_strings":["Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA","Sumitomo Pharma Co., Ltd, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA","institution_ids":["https://openalex.org/I4210140088"]},{"raw_affiliation_string":"Sumitomo Pharma Co., Ltd, Tokyo, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013512751","display_name":"Yu\u2010Luan Chen","orcid":"https://orcid.org/0000-0002-2866-3602","observed_orcids":["https://orcid.org/0000-0002-2866-3602"]},"institutions":[{"id":"https://openalex.org/I4210140088","display_name":"Sumitomo Dainippon Pharma (United States)","ror":"https://ror.org/04vwbmb32","country_code":"US","type":"company","lineage":["https://openalex.org/I31591830","https://openalex.org/I4210140088"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yu-Luan Chen","raw_affiliation_strings":["Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA","institution_ids":["https://openalex.org/I4210140088"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101608050","display_name":"Guangqing Xiao","orcid":"https://orcid.org/0009-0004-5479-9126","observed_orcids":["https://orcid.org/0009-0004-5479-9126","https://orcid.org/0000-0002-1471-3955"]},"institutions":[{"id":"https://openalex.org/I4210140088","display_name":"Sumitomo Dainippon Pharma (United States)","ror":"https://ror.org/04vwbmb32","country_code":"US","type":"company","lineage":["https://openalex.org/I31591830","https://openalex.org/I4210140088"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guangqing Xiao","raw_affiliation_strings":["Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA","institution_ids":["https://openalex.org/I4210140088"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031149394","display_name":"Lisa Lennek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140088","display_name":"Sumitomo Dainippon Pharma (United States)","ror":"https://ror.org/04vwbmb32","country_code":"US","type":"company","lineage":["https://openalex.org/I31591830","https://openalex.org/I4210140088"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa Lennek","raw_affiliation_strings":["Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA","institution_ids":["https://openalex.org/I4210140088"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019761838","display_name":"Snezana M. Milanovic","orcid":"https://orcid.org/0009-0000-7586-1583","observed_orcids":["https://orcid.org/0009-0000-7586-1583","https://orcid.org/0000-0002-4160-9221"]},"institutions":[{"id":"https://openalex.org/I4210140088","display_name":"Sumitomo Dainippon Pharma (United States)","ror":"https://ror.org/04vwbmb32","country_code":"US","type":"company","lineage":["https://openalex.org/I31591830","https://openalex.org/I4210140088"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Snezana M. Milanovic","raw_affiliation_strings":["Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA","institution_ids":["https://openalex.org/I4210140088"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047805456","display_name":"MaryAlice Worden","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140088","display_name":"Sumitomo Dainippon Pharma (United States)","ror":"https://ror.org/04vwbmb32","country_code":"US","type":"company","lineage":["https://openalex.org/I31591830","https://openalex.org/I4210140088"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"MaryAlice Worden","raw_affiliation_strings":["Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA","institution_ids":["https://openalex.org/I4210140088"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111415346","display_name":"Daniel G. Polhamus","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210137375","display_name":"Metrum Research Group (United States)","ror":"https://ror.org/04j2hh758","country_code":"US","type":"company","lineage":["https://openalex.org/I4210137375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel G. Polhamus","raw_affiliation_strings":["Metrum Research Group, Tariffville, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Metrum Research Group, Tariffville, CT, USA","institution_ids":["https://openalex.org/I4210137375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034328634","display_name":"Yu\u2010Yuan Chiu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140088","display_name":"Sumitomo Dainippon Pharma (United States)","ror":"https://ror.org/04vwbmb32","country_code":"US","type":"company","lineage":["https://openalex.org/I31591830","https://openalex.org/I4210140088"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yu-Yuan Chiu","raw_affiliation_strings":["Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA","institution_ids":["https://openalex.org/I4210140088"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063897129","display_name":"Seth C. Hopkins","orcid":"https://orcid.org/0000-0003-3999-2281","observed_orcids":["https://orcid.org/0000-0003-3999-2281"]},"institutions":[{"id":"https://openalex.org/I4210140088","display_name":"Sumitomo Dainippon Pharma (United States)","ror":"https://ror.org/04vwbmb32","country_code":"US","type":"company","lineage":["https://openalex.org/I31591830","https://openalex.org/I4210140088"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Seth C. Hopkins","raw_affiliation_strings":["Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA","institution_ids":["https://openalex.org/I4210140088"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066543290","display_name":"Gerald R. Galluppi","orcid":"https://orcid.org/0000-0001-6705-3084","observed_orcids":["https://orcid.org/0000-0001-6705-3084"]},"institutions":[{"id":"https://openalex.org/I4210140088","display_name":"Sumitomo Dainippon Pharma (United States)","ror":"https://ror.org/04vwbmb32","country_code":"US","type":"company","lineage":["https://openalex.org/I31591830","https://openalex.org/I4210140088"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Gerald R. Galluppi","raw_affiliation_strings":["Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA. gerald.galluppi@sunovion.com","Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA. gerald.galluppi@sunovion.com","institution_ids":[]},{"raw_affiliation_string":"Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA","institution_ids":["https://openalex.org/I4210140088"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5066543290"],"corresponding_institution_ids":["https://openalex.org/I4210140088"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":{"value":4390,"currency":"USD","value_usd":4390},"fwci":0.9159,"has_fulltext":true,"cited_by_count":6,"citation_normalized_percentile":{"value":0.65914221,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":95,"max":97},"biblio":{"volume":"62","issue":"12","first_page":"1755","last_page":"1763"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ulotaront","display_name":"ulotaront","score":0.9980000257492065},{"id":"https://openalex.org/keywords/paroxetine","display_name":"paroxetine","score":0.9750000238418579},{"id":"https://openalex.org/keywords/cyp2d6-inhibition","display_name":"CYP2D6 inhibition","score":0.9549999833106995},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.8939999938011169},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9890000224113464},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.5669999718666077},{"id":"https://openalex.org/keywords/taar1-agonists","display_name":"TAAR1 agonists","score":0.7839999794960022},{"id":"https://openalex.org/keywords/5-ht1a-receptor-agonist","display_name":"5-HT1A receptor agonist","score":0.925000011920929},{"id":"https://openalex.org/keywords/psychotropic-drugs","display_name":"psychotropic drugs","score":0.6830000281333923},{"id":"https://openalex.org/keywords/drug-metabolites","display_name":"drug metabolites","score":0.3720000088214874}],"concepts":[{"id":"https://openalex.org/C33664856","wikidata":"https://www.wikidata.org/wiki/Q3271142","display_name":"CYP2D6","level":4,"score":0.7986974120140076},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7702802419662476},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6948440670967102},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.6516326665878296},{"id":"https://openalex.org/C2777828372","wikidata":"https://www.wikidata.org/wiki/Q408471","display_name":"Paroxetine","level":4,"score":0.6469138860702515},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.5786086320877075},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.479361355304718},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.43661054968833923},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.41183602809906006},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.37807220220565796},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32768237590789795},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.19722330570220947},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.09645876288414001},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.08088544011116028},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011714","descriptor_name":"Pyrans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017374","descriptor_name":"Paroxetine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D019389","descriptor_name":"Cytochrome P-450 CYP2D6","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065690","descriptor_name":"Cytochrome P-450 CYP2D6 Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1007/s40262-023-01317-4","doi":"https://doi.org/10.1007/s40262-023-01317-4","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-023-01317-4","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-023-01317-4.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10684410","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10684410","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10684410/pdf/40262_2023_Article_1317.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacokinet","raw_type":"Text"},{"id":"pmid:37882999","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37882999","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacokinetics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1007/s40262-023-01317-4","doi":"https://doi.org/10.1007/s40262-023-01317-4","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-023-01317-4","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-023-01317-4.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320311407","display_name":"Sunovion","ror":"https://ror.org/030zc7t66"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4387950206.pdf","grobid_xml":"https://content.openalex.org/works/W4387950206.grobid-xml"},"referenced_works_count":25,"referenced_works":["https://openalex.org/W1968073258","https://openalex.org/W1975324279","https://openalex.org/W2001657113","https://openalex.org/W2008998473","https://openalex.org/W2048918525","https://openalex.org/W2119176600","https://openalex.org/W2405524691","https://openalex.org/W2893618043","https://openalex.org/W2964999518","https://openalex.org/W2981329862","https://openalex.org/W3015204490","https://openalex.org/W3022484871","https://openalex.org/W3152702086","https://openalex.org/W3155391591","https://openalex.org/W3162054455","https://openalex.org/W3186490203","https://openalex.org/W3202513049","https://openalex.org/W3213184078","https://openalex.org/W4200032489","https://openalex.org/W4200304329","https://openalex.org/W4200449691","https://openalex.org/W4206571545","https://openalex.org/W4225131709","https://openalex.org/W4327712977","https://openalex.org/W6793765309"],"related_works":["https://openalex.org/W4225131709","https://openalex.org/W4393199103","https://openalex.org/W3186490203","https://openalex.org/W1975071084","https://openalex.org/W2468659783","https://openalex.org/W2148875560","https://openalex.org/W1979177892","https://openalex.org/W4236984048","https://openalex.org/W139215090","https://openalex.org/W3107372878"],"abstract_inverted_index":{"Ulotaront":[0],"is":[1,230,257],"a":[2,42,58,253],"novel":[3],"psychotropic":[4],"agent":[5],"with":[6,103,259],"agonist":[7],"activity":[8],"at":[9],"trace":[10],"amine-associated":[11],"receptor":[12],"1":[13,68],"(TAAR1)":[14],"and":[15,69,137,154,157,243],"5-hydroxytryptamine":[16],"type":[17],"1A":[18,20],"(5-HT":[19],")":[21,136,151,164,209],"receptors":[22],"in":[23,53,227],"phase":[24,222],"III":[25],"clinical":[26],"development":[27],"for":[28],"the":[29,38,140,196,203,213,225,244],"treatment":[30],"of":[31,40,62,73,99,108,125,170,175,218],"schizophrenia.":[32],"This":[33],"study":[34],"aimed":[35],"to":[36,82,84,115,147,195,202,232,265],"investigate":[37],"effect":[39,186],"paroxetine,":[41],"strong":[43,245,260],"cytochrome":[44],"P450":[45],"(CYP)":[46],"2D6":[47],"inhibitor,":[48],"on":[49,66,187,193,212],"ulotaront":[50,65,128,159,197,219,228,242,256],"pharmacokinetics":[51],"(PK)":[52],"healthy":[54],"volunteers.":[55],"Subjects":[56],"received":[57,94],"single":[59,96],"oral":[60,71,97,106],"dose":[61,72,98,250],"25":[63,100],"mg":[64,75,101,110],"Day":[67,91],"an":[70],"20":[74,109],"paroxetine":[76,88,111,126,171],"once":[77],"daily":[78,105],"from":[79,112,144,199],"Days":[80,113],"5":[81],"10":[83],"achieve":[85],"steady-state":[86],"plasma":[87,131,141],"levels.":[89],"On":[90],"11,":[92],"subjects":[93,119],"another":[95],"ulotaront,":[102],"continued":[104],"dosing":[107],"11":[114],"14.":[116],"All":[117],"24":[118],"were":[120,239],"CYP2D6":[121,246,261,266],"normal":[122],"metabolizers.":[123],"Coadministration":[124],"increased":[127,172],"maximum":[129],"observed":[130,240],"concentration":[132,206],"(":[133],"C":[134,189],"max":[135,190],"area":[138],"under":[139],"concentration-time":[142],"curve":[143],"time":[145,200],"zero":[146,201],"infinity":[148],"(AUC":[149,207],"\u221e":[150,174],"by":[152,165,181],"31%":[153],"72%,":[155],"respectively,":[156],"decreased":[158],"apparent":[160],"clearance":[161],"(CL/":[162],"F":[163],"approximately":[166],"42%.":[167],"While":[168],"coadministration":[169],"AUC":[173,198],"active":[176],"but":[177],"minor":[178],"metabolite":[179],"SEP-363854":[180,188,194],"32%,":[182],"it":[183],"had":[184],"no":[185],",":[191],"or":[192,263],"last":[204,208],"quantifiable":[205],"ratio.":[210],"Based":[211],"acceptable":[214],"adverse":[215],"event":[216],"profile":[217],"across":[220],"previous":[221],"II":[223],"studies,":[224],"increase":[226],"exposure":[229],"unlikely":[231],"be":[233,271],"clinically":[234],"meaningful.":[235],"Weak":[236],"drug\u2013drug":[237],"interactions":[238],"between":[241],"inhibitor":[247],"paroxetine;":[248],"however,":[249],"adjustment":[251],"as":[252],"precondition":[254],"when":[255],"coadministered":[258],"inhibitors":[262],"administered":[264],"poor":[267],"metabolizers":[268],"should":[269],"not":[270],"necessary.":[272]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2024,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-10-27T00:00:00"}